Abstract
Erectile dysfunction (ED) is often associated with cardiovascular disease (CVD) and the risk of sildenafilinduced orthostatic hypotension (OH) in subjects with CVD is a matter of concern. We describe our experience in using the tilt test (TT) with continuous plethysmography to evaluate the occurrence of OH in patients with CVD and ED after a test dose of sildenafil. When sildenafil was added on top of their usual pharmacological treatment two patients out of 32 (6.2%) developed asymptomatic OH, with a maximum blood pressure fall of 40/20 mm Hg. The low prevalence and modest clinical relevance of OH in our high-risk population coupled with the known high sensitivity and reproducibility of the TT seem to suggest that sildenafil is haemodynamically safer than is generally believed even when added on top of vasoactive treatment. These findings should be put into perspective against the growing wealth of evidence that PDE5 inhibitors may have therapeutic potential for a number of CV conditions.
Keywords: Erectile disfunction, sildenafil, orthostatic hypotension, drug safety, cardiovascular disease, Tilt Test, Plethysmography, PDE5 inhibitors
Current Drug Safety
Title: Limited Hypotensive Effect of Sildenafil in a High-Risk Population: A Preliminary Report
Volume: 6 Issue: 4
Author(s): M. M. Ciulla, P. Nicolini, C. Benfenati, C. Vecchiato, G. Acquistapace, G. L. Perrucci and F. Magrini
Affiliation:
Keywords: Erectile disfunction, sildenafil, orthostatic hypotension, drug safety, cardiovascular disease, Tilt Test, Plethysmography, PDE5 inhibitors
Abstract: Erectile dysfunction (ED) is often associated with cardiovascular disease (CVD) and the risk of sildenafilinduced orthostatic hypotension (OH) in subjects with CVD is a matter of concern. We describe our experience in using the tilt test (TT) with continuous plethysmography to evaluate the occurrence of OH in patients with CVD and ED after a test dose of sildenafil. When sildenafil was added on top of their usual pharmacological treatment two patients out of 32 (6.2%) developed asymptomatic OH, with a maximum blood pressure fall of 40/20 mm Hg. The low prevalence and modest clinical relevance of OH in our high-risk population coupled with the known high sensitivity and reproducibility of the TT seem to suggest that sildenafil is haemodynamically safer than is generally believed even when added on top of vasoactive treatment. These findings should be put into perspective against the growing wealth of evidence that PDE5 inhibitors may have therapeutic potential for a number of CV conditions.
Export Options
About this article
Cite this article as:
M. Ciulla M., Nicolini P., Benfenati C., Vecchiato C., Acquistapace G., L. Perrucci G. and Magrini F., Limited Hypotensive Effect of Sildenafil in a High-Risk Population: A Preliminary Report, Current Drug Safety 2011; 6 (4) . https://dx.doi.org/10.2174/157488611798280898
DOI https://dx.doi.org/10.2174/157488611798280898 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Therapies for Sepsis
Current Topics in Medicinal Chemistry Perioperative Management of Obese Parturients
Current Women`s Health Reviews Diet and Heart Health: Moderate Wine Drinking Strengthens the Cardioprotective Effects of Fish Consumption
Current Pharmaceutical Biotechnology Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Why Not to Use the Handgrip Test in the Assessment of Cardiovascular Autonomic Neuropathy Among Patients with Diabetes Mellitus?
Current Vascular Pharmacology Advances in L-Type Calcium Channel Structures, Functions and Molecular Modeling
Current Medicinal Chemistry Small Interfering RNAs and Antisense Oligonucleotides for Treatment of Neurological Diseases
Current Drug Targets Pediatric Chronic Daily Headache
Current Pediatric Reviews Heat Shock Protein Inhibitors for the Treatment of Fungal Infections
Recent Patents on Anti-Infective Drug Discovery Endothelial Dysfunction in Heart Failure: Mechanisms and Therapeutic Approaches
Current Vascular Pharmacology Cancer Treatment-Induced Cardiotoxicity: a Cardiac Stem Cell Disease?
Cardiovascular & Hematological Agents in Medicinal Chemistry Review of Vital Signs Monitoring Systems – Patient’s Acceptability, Issues and Challenges
Neuroscience and Biomedical Engineering (Discontinued) Neurogenesis and Sensorimotor Gating: Bridging a Microphenotype and an Endophenotype
Current Molecular Medicine Clinical Pharmacology of Frequently Used Intravenous Drugs During Bariatric Surgery in Adolescents
Current Pharmaceutical Design Monoamine Oxidases: to Inhibit or Not to Inhibit
Mini-Reviews in Medicinal Chemistry Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity
Current Cancer Drug Targets Cannabinoids and Cardiovascular Disease: The Outlook for Clinical Treatments
Current Vascular Pharmacology Hypotensive Agents from Snake Venoms
Current Drug Targets - Cardiovascular & Hematological Disorders Current Treatment of Autoimmune Blistering Diseases
Current Drug Discovery Technologies Single-dose Pharmacokinetics and Tolerability of Oral Delta-9- Tetrahydrocannabinol in Patients with Amyotrophic Lateral Sclerosis
Drug Metabolism Letters